secwatch.observer — SEC 8-K summary
======================================

Issuer:     Quince Therapeutics, Inc. (QNCX)
CIK:        0001662774
Form:       8-K
Filed at:   2022-08-01T23:59:59+00:00
Accession:  0001193125-22-207867
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 5.03, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cortexyme rebrands as Quince Therapeutics, shifts to bone-targeting drugs, reports $105M cash
--------------------------------------------------------------------------------

- Cash, cash equivalents and short-term investments: ~$105M as of June 30, 2022 (preliminary).
- Name changed from Cortexyme to Quince Therapeutics; ticker changes from CRTX to QNCX effective Aug 1, 2022.
- Strategic focus on bone-targeting drug platform and lead molecule NOV004; Phase 1 clinical studies expected in 2023.
- Plans to in-license or acquire clinical-stage assets for debilitating/rare diseases and out-license legacy neuroscience assets.
- Cash runway expected to fund operations into second half of 2025; corporate restructuring completed in H1 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1662774/000119312522207867/0001193125-22-207867-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1662774/000119312522207867/d346512d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-207867

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer